PicnicHealth announced that its research collaboration with Neurocrine Biosciences, Inc., the CAHtalog Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). The study, using PicnicHealth's AI-powered technology, revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing to maintain condition control.
The CAHtalog Registry, founded in 2021 by PicnicHealth and Neurocrine in collaboration with the CARES Foundation, aims to advance patient-centered research and enhance scientific knowledge of CAH. Conducting longitudinal studies on rare diseases like CAH is challenging, but tech-enabled research models improve access and participation by minimizing the burden of in-person visits.
This study demonstrates how researchers can gather valuable, long-term insights while minimizing patient burden. The findings highlight the ongoing complexity of managing CAH and the need for advanced therapeutic options, reinforcing the market opportunity for CRENESSITY.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.